Advertisement Pharmaceutical Business review - Page 579 of 5224 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 28, 2024

FDA grants IND clearance for RiboX’s RXRG001

The US Food and Drug Administration (FDA) has granted clearance for RiboX Therapeutics’ investigational new drug (IND) application to commence a Phase I/IIa clinical trial of RXRG001, circular RNA therapy.

Xerostomia and hyposalivation are complications seen in patients undergoing radiation treatment for head and neck cancer. Credit: Myriam Zilles on Unsplash.